Eltrombopag (Revolade®) is recommended for use within NHS Wales in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon based therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.